As you might know, COSMOS Pharmaceutical Corporation (TSE:3349) recently reported its first-quarter numbers. Results were roughly in line with estimates, with revenues of JP¥287b and statutory earnings per share of JP¥104. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on COSMOS Pharmaceutical after the latest results.
After the latest results, the ten analysts covering COSMOS Pharmaceutical are now predicting revenues of JP¥1.18t in 2027. If met, this would reflect an okay 5.5% improvement in revenue compared to the last 12 months. Statutory per share are forecast to be JP¥405, approximately in line with the last 12 months. Before this earnings report, the analysts had been forecasting revenues of JP¥1.18t and earnings per share (EPS) of JP¥405 in 2027. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
See our latest analysis for COSMOS Pharmaceutical
The analysts reconfirmed their price target of JP¥7,510, showing that the business is executing well and in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values COSMOS Pharmaceutical at JP¥9,600 per share, while the most bearish prices it at JP¥6,700. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the COSMOS Pharmaceutical's past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of COSMOS Pharmaceutical'shistorical trends, as the 7.5% annualised revenue growth to the end of 2027 is roughly in line with the 9.1% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 3.3% per year. So although COSMOS Pharmaceutical is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for COSMOS Pharmaceutical going out to 2029, and you can see them free on our platform here..
You can also view our analysis of COSMOS Pharmaceutical's balance sheet, and whether we think COSMOS Pharmaceutical is carrying too much debt, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.